Integra LifeSciences Holdings Corporation reported its financial results for the second quarter ending June 30, 2025. Total reported revenues were $415.6 million, a decrease of 0.6% on a reported basis and 1.4% organically compared to the prior year. The company reported a GAAP net loss of $(484.1) million, or $(6.31) per diluted share, primarily driven by a non-cash goodwill impairment charge of $511.4 million.
Adjusted net income for the second quarter was $34.4 million, or $0.45 per diluted share, compared to $49.0 million, or $0.63 per diluted share, in the prior year. GAAP gross margin was 50.4%, down from 54.0% in Q2 2024, while adjusted gross margin was 60.7% compared to 65.2%. The company highlighted disciplined progress on its Compliance Master Plan, with all internal manufacturing site assessments completed ahead of schedule and no new material shipholds identified in Q2 2025.
For the full year 2025, Integra LifeSciences updated its revenue guidance range to $1.655 billion to $1.680 billion, representing reported growth of 2.8% to 4.3% and organic growth of 0.6% to 2.1%. The full-year adjusted EPS guidance was reaffirmed at $2.19 to $2.29 per share. For the third quarter of 2025, the company expects revenues between $410 million and $420 million, with adjusted EPS in the range of $0.40 to $0.45.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.